Forum Article · Volume 2, Issue 3 · pp. 97–98
Nonviral gene delivery system
Ningning Yang1
- 1Department of Pharmaceutical Sciences, Manchester University College of Pharmacy, 10627 Diebold Road, Fort Wayne, IN 46845, USA.
Abstract
Gene therapy has been investigated a lot in both basic research and clinical trials.[1] The first antisense oligodeoxyribonucleotide (ODN) drug, Vitravene (Fomivirsen), was approved by the United States Food and Drug Administration (FDA) in 2005.[2] After this approval, more and more clinical trials are conducted, not only for ODNs, but also for other nucleic acids drugs, such as plasmid vectors and small interference RNAs (siRNAs).
The full text of this article is available as a PDF. Open the PDF.